Literature DB >> 1782783

Ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with AIDS.

R Belfort1, M de Smet, S M Whitcup, C Pavesio, C Lottenberg, B Rubin, J S Lopez, R Nussenblatt.   

Abstract

Recent reports suggest that acquired immunodeficiency syndrome (AIDS) patients are at higher risk of developing mucocutaneous reactions such as toxic epidermal necrolysis and Stevens-Johnson syndrome (SJS). Resultant dry eye may be further exacerbated by human immunodeficiency virus (HIV) related lacrimal gland dysfunction and lead to a chronic keratoconjunctivitis. We report one patient with AIDS and toxic epidermal necrolysis and two patients with AIDS and SJS who developed severe dry eye misdiagnosed as infectious keratoconjunctivitis. Cicatrizing mucocutaneous reactions should be suspected in AIDS patients and the dry eye treated to control symptoms and prevent complications.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1782783     DOI: 10.1097/00003226-199111000-00013

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  3 in total

Review 1.  Amniotic membrane transplantation as a new therapy for the acute ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis.

Authors:  Elizabeth Shay; Ahmad Kheirkhah; Lingyi Liang; Hossam Sheha; Darren G Gregory; Scheffer C G Tseng
Journal:  Surv Ophthalmol       Date:  2009-08-21       Impact factor: 6.048

2.  Prevalence of chronic ocular complications in Stevens-Johnson syndrome and toxic epidermal necrolysis.

Authors:  Lourens Van Zyl; Henry Carrara; Karin Lecuona
Journal:  Middle East Afr J Ophthalmol       Date:  2014 Oct-Dec

3.  Factors Contributing to Long-Term Severe Visual Impairment in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Authors:  Passara Jongkhajornpong; Kaevalin Lekhanont; Sukanya Siriyotha; Silada Kanokrungsee; Varintorn Chuckpaiwong
Journal:  J Ophthalmol       Date:  2017-03-26       Impact factor: 1.909

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.